Findings

What do systematic reviews say?

8 questions · 8 findings · 2 reviews · Hepato-Biliary

No studies found 4 · 50%GRADE not reported 0 · 0%Very low 4 · 50%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Serious adverse events (number) · alcohol‐related disorders (others)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events (proportion) · alcohol‐related disorders (others)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events (number) · participants with severe alcoholic hepatitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events (number) · participants with alcoholic hepatitis (all severity)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Serious adverse events (proportion) · participants with severe alcoholic hepatitis

It is very uncertain whether glucocorticosteroids changes serious adverse events (proportion) compared with no intervention (very low certainty).

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
OR 1.37 [0.98, 1.93]
1 study · 546 participants
Very low

Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity)

It is very uncertain whether glucocorticosteroids changes serious adverse events (proportion) compared with no intervention (very low certainty).

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
OR 1.37 [0.98, 1.93]
1 study · 546 participants
Very low

Serious adverse events during treatment · participants with alcoholic hepatitis at high risk of mortality and morbidity

It is very uncertain whether the intervention changes serious adverse events during treatment (very low certainty).

1 finding from 1 review

Glucocorticosteroids for people with alcoholic hepatitis 2019 · Cochrane Headline outcomes only
RR 1.05 [0.85, 1.29]
15 studies · 1861 participants
Very low

Participants with non‐serious adverse events: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity

It is very uncertain whether the intervention changes participants with non‐serious adverse events: up to 3 months' (very low certainty).

1 finding from 1 review

Glucocorticosteroids for people with alcoholic hepatitis 2019 · Cochrane Headline outcomes only
RR 1.99 [0.72, 5.48]
4 studies · 160 participants
Very low